TRANSCATHETER AORTIC VALVE IMPLANTATION WITH USE OF BIVALIRUDIN IN PATIENT WITH HEPARIN-INDUCED THROMBOCYTOPENIA. CLINICAL CASE

Cover Page

Cite item

Full Text

Abstract

In the paper the authors report the first in Russia clinical case of successful transcatheter aortic valve implantation in high-risk patient with critical aortic stenosis and verified heparin-induced thrombocytopenia type 2 with use of direct thrombin inhibitor bivalirudin. The key issues of pathogenetic and diagnostical issues of verified heparin-induced thrombocytopenia, and up-to-date clinical evidence of bivalirudin as alternative medication for the controlled procedural anticoagulation in the setting of contraindication for heparin use are highlighted in the literature review.

About the authors

Aleksei E. Komlev

National Medical Research Center of Cardiology

кардиолог отд. сердечно-сосудистой хирургии Moscow, Russia

Valentina V. Romakina

National Medical Research Center of Cardiology

Email: dr513@mail.ru
кардиолог отд. сердечно-сосудистой хирургии Moscow, Russia

Timur E. Imaev

National Medical Research Center of Cardiology

д-р мед. наук, гл. науч. сотр. отд. сердечно-сосудистой хирургии Moscow, Russia

Aleksandr S. Kolegaev

National Medical Research Center of Cardiology

канд. мед. наук, науч. сотр. отд. сердечно-сосудистой хирургии Moscow, Russia

Renat S. Akchurin

National Medical Research Center of Cardiology

акад. РАН, д-р мед. наук, проф., рук. отд. сердечно-сосудистой хирургии Moscow, Russia

References

  1. Warkentin TE, Greinacher A. So, does low-molecular-weight heparin cause less heparin-induced thrombocytopenia than unfractionated heparin or not? Chest 2007; 132 (4): 1108-10. doi: 10.1378/chest.07-1553
  2. Datta I, Ball CG, Rudmik L et al. Complications related to deep venous thrombosis prophylaxis in trauma: a systematic review of the literature. J Trauma Manag Outcomes 2010; 4: 1. doi: 10.1186/1752-2897-4-1
  3. Arepally GM, Ortel TL. Clinical practice. Heparin-induced thrombocytopenia. N Engl J Med 2006; (8): 809-17. doi: 10.1056/NEJMcp052967
  4. Watson H, Davidson S, Keeling D. Haemostasis and Thrombosis Task Force of the British Committee for Standards in Haematology. Guidelines on the diagnosis and management of heparin-induced thrombocytopenia: second edition. Br J Haematol 2012; 159: 528-40. doi: 10.1111/bjh.12059
  5. Seigerman M, Cavallaro P, Itagaki S et al. Incidence and outcomes of heparin-induced thrombocytopenia in patients undergoing cardiac surgery in North America: An analysis of the nationwide inpatient sample. J Cardiothorac Vasc Anesth 2014; 28: 98-102. doi: 10.1053/j.jvca.2013.07.021
  6. Glance LG, Blumberg N, Eaton M et al. Preoperative thrombocytopenia and postoperative outcomes after noncardiac surgery. Anesthesiology 2014; 120 (1): 62-75. doi: 10.1097/ALN.0b013e3182a4441f
  7. Matthai WH. Thrombocytopenia in Cardiovascular Patients: diagnosis and Management. Chest 2005; 127 (Suppl. 2): 46S-52S. doi: 10.1378/chest.127.2_suppl.46S
  8. Васильев С.А., Горгидзе Л.А., Моисеева Т.Н. и др. Гепарининдуцированная тромбоцитопения (обзор). Атеротромбоз. 2019; 1: 99-114. doi: 10.21518/2307-1109-2019-1-99-114
  9. Марченко И.А., Шиян А.В., Андреева А.С. Современные методы лабораторной диагностики гепарин-индуцированной тромбоцитопении. Мед. совет. 2017; 12: 189-95.
  10. Семиголовский Н.Ю., Семиголовский С.Н. Патогенез, диагностика и лечение тромбоцитопений. Поликлиника.2015; 7: 20-5.
  11. Warkentin TE, Greinacher A, Koster A et al. Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133: 340-80. doi: 10.1378/chest.08-0677
  12. Bleasel JF, Rasko JE, Rickard KA et al. Acute adrenal insufficiency secondary to heparin-induced thrombocytopenia-thrombosis syndrome. Med J Aust 1992; 157 (3): 192-3.
  13. Ivascu NS, Fitzgerald M, Ghadimi K et al. Heparin-induced thrombocytopenia: a review for cardiac anesthesiologists and intensivists. J Cardiothorac Vasc Anesth 2019; 33 (2): 511-20. doi: 10.1053/j.jvca.2018.10.035
  14. Kodali SK, Williams MR, Smith CR et al. Two-year outcomes after transcatheter or surgical aortic-valve replacement. N Engl J Med 2012; 366 (18): 1686-95. doi: 10.1056/NEJMoa1200384
  15. Reardon MJ, Adams DH, Kleiman NS et al. 2-Year Outcomes in Patients Undergoing Surgical or Self-Expanding Transcatheter Aortic Valve Replacement. J Am Coll Cardiol 2015; 66 (2): 113-21. doi: 10.1016/j.jacc.2015.05.017
  16. Stone GW, Witzenbichler B, Guagliumi G et al. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med 2008; 358 (21): 2218-30. doi: 10.1056/NEJMoa0708191
  17. Stone GW, McLaurin BT, Cox DA et al. Bivalirudin for patients with acute coronary syndromes. N Engl J Med 2006; 355 (21): 2203-16. doi: 10.1056/NEJMoa062437
  18. Choxi AA, Patel PA, Augoustides JG et al. Bivalirudin for cardiopulmonary bypass in the setting of heparininduced thrombocytopeniya and combined yeart and ridney transplantation-diagnostic and therapeutic Challenges. J Cardiothorac Vasc Anesth 2017; 31 (1): 354-64. doi: 10.1053/j.jvca.2016.07.009
  19. Merry AF, Raudkivi PJ, Middleton NG et al. Bivalirudin versus heparin and protamine in off-pump coronary artery bypass surgery. Ann Thorac Surg 2004; 77 (3): 925-31; discussion 931. doi: 10.1016/j.athoracsur.2003.09.061
  20. Smedira NG, Dyke CM, Koster A et al. Anticoagulation with bivalirudin for off-pump coronary artery bypass grafting: the results of the EVOLUTION-OFF study. J Thorac Cardiovasc Surg 2006; 131 (3): 686-92. doi: 10.1016/j.jtcvs.2005.10.049
  21. Dyke CM, Aldea G, Koster A et al. Off-pump coronary artery bypass with bivalirudin for patients with heparin-induced thrombocytopenia or antiplatelet factor four/heparin antibodies. Ann Thorac Surg 2007; 84 (3): 836-9. doi: 10.1016/j.athoracsur.2007.04.007
  22. Kini A, Yu J, Cohen MG et al. Effect of bivalirudin on aortic valve intervention outcomes study: a two-center registry study comparing bivalirudin and unfractionated heparin in balloon aortic valvuloplasty. Euro Intervention 2014; 10 (3): 312-9. doi: 10.4244/EIJV10I3A54
  23. Lange P, Greif M, Bongiovanni D et al. Bivalirudin vs Heparin in Patients Who Undergo Transcatheter Aortic Valve Implantation. Can J Cardiol 2015; 31 (8): 998-1003. doi: 10.1016/j.cjca.2015.02.029
  24. Dangas GD, Lefevre T, Kupatt C et al. Bivalirudin Versus Heparin Anticoagulation in Transcatheter Aortic Valve Replacement: The Randomized BRAVO-3 Trial. J Am Coll Cardiol 2015; 66 (25): 286068. doi: 10.1016/j.jacc.2015.10.003

Copyright (c) 2020 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies